trial
as of 2026-07-01Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
NCTId NCT00469664
at a glance
Phase 4 · Unknown
Enrollment 50 (estimated)
Sponsored by Research Foundation for Mental Hygiene, Inc.
Primary completion 2008-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Unknown
Enrollment
50 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2000-02
Primary completion
2008-08
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Research Foundation for Mental Hygiene, Inc.Lead Sponsor
Bronx VA Medical CenterCollaborator
Icahn School of Medicine at Mount SinaiCollaborator
Investigators
1
Joseph I. Friedman, MDPrincipal Investigator
Sites
3 total
New York, United StatesThe Bronx, United StatesW. Brentwood, United States
Facts & assertions
4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2008-08
Status
UNKNOWN
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person